Detection of solitary bone metastasis by 99mTc-octreotide scintigraphy in a patient with Hurthle cell carcinoma: A case report

Document Type : Case Report


Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran


A 75-year-old male patient with non-avid radioiodine Hurthle cell carcinoma was evaluated by 99m Tc- octreotide scintigraphy, in order to find possible metastatic lesions. A bony metastatic lesion was detected by this procedure which was confirmed by histopathology.99mTc-octreotide scintigraphy is a precise and cost-effective imaging modality for detection of non-iodine avid lesions in metastatic differentiated thyroid carcinomas.


Main Subjects

  1. Lowe VJ, Mullan BP, Hay ID, McIver B, Kasperbauer JL. 18F-FDG PET of patients with Hürthle cell carcinoma. J Nucl Med. 2003 Sep;44(9):1402-6.
  2. Zhang H, Zeng L, Liang C, Qiu H, Zhang M, Zhu Y, Xie C. Successful treatment of Hurthle cell thyroid carcinoma with lung and liver metastasis using docetaxel and cisplatin. Jpn J Clin Oncol. 2012 Nov;42(11):1086-90.
  3. Khan S, Sharibi A, Neff R, Grace W, Young IS. Metastatic Hürthle cell carcinoma: a unique case report and review of the literature. Endocr Pract. 2005 Jul-Aug;11(4):285-9.
  4. Pryma DA, Schöder H, Gönen M, Robbins RJ, Larson SM, Yeung HW. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med. 2006 Aug;47(8):1260-6.
  5. Shinto AS, Kamaleshwaran K, Mallia M, Korde A, Samuel G, Banerjee S, Velayutham P, Damodharan S, Sairam M. Utility of 99mTc-Hynic-TOC in 131I whole-body scan negative thyroid cancer patients with elevated serum thyroglobulin levels. World J Nucl Med. 2015;14(2):101-108.
  6. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996 Sep;37(9):1468-72.
  7. Haslinghuis LM, Krenning EP, De Herder WW, Reijs AE, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 2001 Jun;24(6):415-22.
  8. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab. 1996 Jul;81(7):2541-4.
  9. Czepczyński R, Gryczyńska M, Ruchała M. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment. Nucl Med Rev Cent East Eur. 2016;19(2):67-73.
  10. Robbins RJ, Hill RH, Wang W, Macapinlac HH, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid. 2000 Feb;10(2):177-83.